Follow the Akeso, Inc. stock price and the full management transaction log of the company, a publicly traded company based in Hong Kong. Shares are listed on the HK market, under the supervision of HKEX. Market capitalisation: €83.1bn. The latest transaction was disclosed on 31 July 2026 (Purchase). Among the most active insiders: Xia Yu. The full history is free.
10
Insider Decl.
n/a
Thresholds
€3m
10 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Akeso, Inc. Strong Buy (bullish), based on 21 analysts. Average price target: HK$168.01.
19Σ signal
Buys €3mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,267 of 29,068 companies
33.3
score / 100
Value
29
Quality
37
FCF yld-2.1%
Earn yld-1.3%
EV/EBITDA·
ROE-14%
Gross mgn79%
Net mgn-36%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
100,000 shares@ HK$87.563548.2% of flowShareXHKGHKEX:DA20260615E00307
10 of 10 declarations
About Akeso, Inc.
Akeso, Inc. is a biopharmaceutical company focused on developing innovative treatments for autoimmune diseases and cancers. It specializes in the research and commercialization of monoclonal antibody-based drugs.